Franck Chiappini
Overview
Explore the profile of Franck Chiappini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gansevoort M, Wentholt S, Li Vecchi G, de Vries M, Versteeg E, Boekema B, et al.
J Funct Biomater
. 2025 Feb;
16(2).
PMID: 39997585
Fibrosis after full-thickness wound healing-especially after severe burn wounds-remains a clinically relevant problem. Biomaterials that mimic the lost dermal extracellular matrix have shown promise but cannot completely prevent scar formation....
2.
Coilly A, Desterke C, Kascakova S, Chiappini F, Samuel D, Vibert E, et al.
Lab Invest
. 2024 Jul;
104(9):102110.
PMID: 39004345
Liver transplantation (LT) is a major treatment for patients with end-stage liver diseases. Steatosis is a significant risk factor for primary graft nonfunction and associated with poor long-term graft outcomes....
3.
Pereira P, Papy-Garcia D, Barritault D, Chiappini F, Jackisch R, Schimchowitsch S, et al.
Glycoconj J
. 2022 Mar;
39(1):107-130.
PMID: 35254602
Using a partial hippocampal cholinergic denervation model, we assessed the effects of the RGTA named OTR4132, a synthetic heparan-mimetic biopolymer with neuroprotective/neurotrophic properties. Long-Evans male rats were injected with the...
4.
Coilly A, Desterke C, Guettier C, Samuel D, Chiappini F
Sci Rep
. 2019 Dec;
9(1):19785.
PMID: 31874999
Nonalcoholic fatty liver (NAFLD) may progress to nonalcoholic steatohepatitis (NASH) and ultimately to cirrhosis and hepatocellular carcinoma (HCC). Prognostic markers for these conditions are poorly defined. The aim of this...
5.
Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA in Dogs
Martinez J, Chiappini F, Barritault D
Vet Sci
. 2019 Dec;
6(4).
PMID: 31847217
Superficial corneal ulcers that fail to heal within a normal time period and are refractory to conventional therapy in dogs are common in veterinary practice. Different etiologies can lead to...
6.
Desterke C, Chiappini F
Int J Mol Sci
. 2019 Nov;
20(22).
PMID: 31717414
Nonalcoholic steatohepatitis (NASH) is becoming a public health problem worldwide. While the number of research studies on NASH progression rises every year, sometime their findings are controversial. To identify the...
7.
Jacquet-Guibon S, Dupays A, Coudry V, Crevier-Denoix N, Leroy S, Sineriz F, et al.
PLoS One
. 2018 Mar;
13(3):e0191796.
PMID: 29522564
A randomized controlled trial was performed on racing horses, to evaluate the efficacy of a new class of therapeutic agents in regenerative medicine-ReGeneraTing Agents® (RGTA®), to treat tendinopathies. Preliminary uncontrolled...
8.
Darnaud M, Dos Santos A, Gonzalez P, Augui S, Lacoste C, Desterke C, et al.
Gastroenterology
. 2017 Nov;
154(4):1009-1023.e14.
PMID: 29133078
Background & Aims: Paneth cell dysfunction causes deficiencies in intestinal C-type lectins and antimicrobial peptides, which leads to dysbiosis of the intestinal microbiota, alters the mucosal barrier, and promotes development...
9.
Chiappini F, Coilly A, Kadar H, Gual P, Tran A, Desterke C, et al.
Sci Rep
. 2017 Apr;
7:46658.
PMID: 28436449
Nonalcoholic steatohepatitis (NASH) is a condition which can progress to cirrhosis and hepatocellular carcinoma. Markers for NASH diagnosis are still lacking. We performed a comprehensive lipidomic analysis on human liver...
10.
Chiappini F, Desterke C, Bertrand-Michel J, Guettier C, Le Naour F
Sci Rep
. 2016 Aug;
6:31587.
PMID: 27510159
Nonalcoholic fatty liver (NAFL) is a precursor of nonalcoholic steatohepatitis (NASH), a condition that may progress to cirrhosis and hepatocellular carcinoma. Markers for diagnosis of NASH are still lacking. We...